Novartis' Foray Into Academia
Executive Summary
Novartis' decision to relocate its discovery operation to Cambridge, MA has garnered considerable attention for what it says about the decline of Europe's competitiveness in the pharmaceutical industry and the increasing attraction of the Boston area for drug and biotech firms. But perhaps even more significant is what the transatlantic move reveals about Novartis' intention to fundamentally change its approach to drug discovery research and what that transformation may mean for the industry in general.
You may also be interested in...
FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility
The US FDA’s device center has unveiled a new public dataset designed to assist chemistry laboratories in ensuring the robustness of chemical characterization methods used to assess the biocompatibility of medical devices.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.